Simply Wall St.1d agoneutral
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin RecoveryNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
102last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...Simply Wall St.3d agobullish
Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial DataMT Newswires5d agoneutral
UBS Adjusts Price Target on Iovance Biotherapeutics to $8 From $7, Maintains Neutral RatingInvestor's Business Daily9d agobearish
Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer TwistSimply Wall St.9d agoneutral
Iovance Biotherapeutics (IOVA) Posts 59.1% Response In Lifileucel Lung Cancer Study